LENZ Therapeutics, Inc. (LENZ) Stock

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is led by CEO Evert Schimmelpennink, employs 6 people, headquartered in US, publicly traded since 2024.

LENZ Therapeutics, Inc. (LENZ) stock trades at $3.16 with a market capitalization of $99.29M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.87, reflecting a net loss over the last twelve months, price-to-book of 0.51, price-to-sales of 5.21. Over the past 52 weeks the stock has ranged between $3.09 and $49.85, and currently trades 93.7% below its 52-week high.

On profitability, LENZ Therapeutics, Inc. generates a return on equity (ROE) of -53.39% (negative, reflecting a net loss), return on capital employed of -61.84%, an operating margin of -478.95%, a net profit margin of -586.74%.

LENZ Therapeutics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 LENZ Therapeutics, Inc. reported revenue of $0 rising to $19.0M. Compounded, revenue has grown —% a year over five years, 8.2% over three, —% over the last twelve months. Net profit was $-82.0M in 2025.

The most recent net margin is -586.74%. On a trailing twelve-month basis to Jun '26, revenue is $22.0M and net profit $-126.0M.

Borrowings fell from $2.0M to $1.0M, cash from operations was $-69.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged 115.0% over five years, and was -28.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

LENZ Therapeutics, Inc. (LENZ) — frequently asked questions